Uterine cervical firmness. Diseases of the genitourinary system
Conditions
Interventions
Intervention 1: Control group: tablet 40 mg Vitamin B 6, vaginal, two doses, 8 hours and 2 hours before the procedure. Intervention 2: Intervention group:tablet Hyoscin Butyl Bromide 10 mg , first
Placebo
Treatment - Drugs
Control group: tablet 40 mg Vitamin B 6, vaginal, two doses, 8 hours and 2 hours before the procedure.
Intervention group:tablet Hyoscin Butyl Bromide 10 mg , first dose 8 hours and the second dose 2 hours before the procedure, vaginally
Sponsors
Vice chancellor for research, Shahid Beheshti University of Medical Science.
Eligibility
Sex/Gender
Female
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: women with gynecological diseases who were scheduled for curettage; Good general health; Want to participate in the study after it is explained; Increased endometrial thickness in sonography evaluation or irregular endometrial echo in sonographic view; Uterine cervical firmness in examination. Exclusion Criteria: abundant vaginal bleeding; use of hormone replacement therapy lately; history of hypersensitivity to or contraindication of the Hyoscin usage.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine cervical dilatation. Timepoint: at the beginning of the study , then 2 hours after the second dose of the investigating drug. Method of measurement: Budgie.;Uterine cervical consistancy. Timepoint: at the beginning of the study , then 2 hours after the second dose of the investigating drug. Method of measurement: passing number 2 Currett through uterine cervix and see its resistance. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tackykardia. Timepoint: 2 hours after the second dose of the drug (at the beginning of the procedure). Method of measurement: Questionnaire.;Uterine perforation. Timepoint: when the device passed through the cervical canal. Method of measurement: Examination.;Tearing of the uterine cervix. Timepoint: when the device passed through the cervical canal. Method of measurement: Examination.;Mouth dryness. Timepoint: 2 hours after the second dose of the drug (at the beginning of the procedure). Method of measurement: Questionnaire.;Nausea and vomitting. Timepoint: 2 hours after the second dose of the drug (at the beginning of the procedure). Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Shiva Hadadian
Shahid Beheshti University of Medical Science
Outcome results
None listed